Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
KLRK1 Biologics Sequence Review Report 2026: NKG2-D type II integral membrane protein Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of KLRK1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KLRC2 Biologics Sequence Review Report 2026: NKG2-C type II integral membrane protein Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of KLRC2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KLRC1 Biologics Sequence Review Report 2026: NKG2-A/NKG2-B type II integral membrane protein Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of KLRC1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PTPRG Biologics Sequence Review Report 2026: Receptor-type tyrosine-protein phosphatase gamma Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of PTPRG protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PTPRE Biologics Sequence Review Report 2026: Receptor-type tyrosine-protein phosphatase epsilon Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of PTPRE protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FCGR2A Biologics Sequence Review Report 2026: Low affinity immunoglobulin gamma Fc region receptor II-a Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FCGR2A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FCGR1A Biologics Sequence Review Report 2026: High affinity immunoglobulin gamma Fc receptor I Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FCGR1A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CD79A Biologics Sequence Review Report 2026: B-cell antigen receptor complex-associated protein alpha chain Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD79A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PTPRA Biologics Sequence Review Report 2026: Receptor-type tyrosine-protein phosphatase alpha Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of PTPRA protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CD36 Biologics Sequence Review Report 2026: Platelet glycoprotein 4 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD36 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CD3G Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD3 gamma chain Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD3G protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FCGR3A Biologics Sequence Review Report 2026: Low affinity immunoglobulin gamma Fc region receptor III-A Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FCGR3A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.